Antimicrobial therapy of Staphylococcus aureus bloodstream infection

Evelina Tacconelli, Maria A. Cataldo

Research output: Contribution to journalArticlepeer-review


Staphylococcus aureus bloodstream infection (BSI) contributes significantly to the morbidity and mortality of in-patients. The optimal therapy for methicillin-susceptible S. aureus BSI consists of penicillins. The efficacy of these drugs is well documented from several published data and supported from a long clinical experience. Methicillin-resistant S. aureus (MRSA) strains are responsible for the majority of nosocomial BSI and are recovered with increasing frequency at hospital admission. Although glycopeptides still represent the drugs of choice, there are several concerns on the treatment of MRSA BSI: reports of clinical failure with vancomycin treatment, regardless of the in vitro susceptibility; increasing reports of MRSA strains with reduced vancomycin susceptibility; difficulty in therapeutic dosage monitoring of teicoplanin; lack of evidence on the efficacy of combination therapy. Recently, new drugs have been introduced in the therapeutic arsenal for MRSA infections, but their clinical use is not yet clearly established for BSI. The review summarises evidence on present therapeutic options for the treatment of S. aureus BSI.

Original languageEnglish
Pages (from-to)2505-2518
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Issue number15
Publication statusPublished - Oct 2007


  • Bloodstream infection
  • Daptomycin
  • Linezolid
  • Methicillin-resistant Staphylococcus aureus
  • Methicillin-susceptible Staphylococcus aureus
  • Quinupristin-dalfopristin
  • Teicoplanin
  • Tigecycline
  • Vancomycin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Antimicrobial therapy of Staphylococcus aureus bloodstream infection'. Together they form a unique fingerprint.

Cite this